Loading
A phase 3 trial of Tucidinostat, Sintilimab, Bevacizumab in colorectal cancer, run by Chipscreen Biosciences, Ltd., now recruiting.
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients is a phase 3 interventional study registered as NCT06497985 by Chipscreen Biosciences, Ltd., with 430 participants planned, started 2024-12-06 and due to reach its primary completion in 2028-05-31. Interventions recorded: Tucidinostat, Sintilimab, Bevacizumab, Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Tucidinostat (chidamide), Fruquintinib, Sintilimab, Anti-angiogenic therapy.
Shares Tucidinostat (chidamide), Fruquintinib, Sintilimab, Anti-angiogenic therapy.
Shares Tucidinostat (chidamide), Fruquintinib, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Sintilimab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Sintilimab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Fruquintinib, Sintilimab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer, Immune checkpoint inhibitors.
Shares Sintilimab, Bevacizumab, Monoclonal antibodies, Immune checkpoint inhibitors.